Latest Content

Life After MDS and Accomplishing Your Goals

January 28th 2025, 6:00pm

By Jane Biehl Ph.D.

Article

After a long and difficult journey, I finally published the book I set out to write as my legacy, overcoming cancer and the challenges of deafness.

Identifying Drivers of Exceptional Response to Immunotherapy in Metastatic RCC

January 28th 2025, 4:09pm

By Ryan Scott

Article

In patients with RCC, exceptional response to immunotherapy may be related to clonal neoantigen-driven cytotoxic T-cell responses, among other factors.

An Expert Shares Her Advice For Managing Side Effects in Cervical Cancer

January 28th 2025, 2:00pm

By Dr. Ritu Salani

Video

Dr. Ritu Salani shared her advice for patients undergoing advanced treatment options for their cervical cancer who are experiencing side effects.

FDA Approves Enhertu for HER2-Low and -Ultralow Breast Cancer

January 28th 2025, 12:22am

By Darlene Dobkowski, MA

Article

The antibody drug conjugate was approved for patients with unresectable or metastatic HER2-low or -ultralow breast cancer with disease progression after endocrine therapy.

Palliative Care May Improve Quality of Life in Esophageal Cancer

January 27th 2025, 10:00pm

By Tim Cortese

Article

End-of-life palliative care consultations may also ease financial strain for patients with esophageal cancer.

Understanding Food Insecurity and Malnutrition During Cancer Treatment

January 27th 2025, 8:00pm

By Ryan Scott

Article

Dr. Anna Arthur discusses how the NOURISH trial is addressing food insecurity and malnutrition in patients undergoing treatment for their blood cancers.

When A Spouse Dies from Cholangiocarcinoma: Praise for Single Parents

January 27th 2025, 6:00pm

By Diana M. Martin

Article

Despite the initial shock and challenges, I found strength and support within the community of single parents.

Oral Liporaxel May Be Superior To Intravenous in Advanced Gastric Cancer

January 27th 2025, 4:14pm

By Ryan Scott

Article

Among those with advanced gastric cancer, oral Liporaxel showed superior overall survival outcomes versus IV Liporaxel as a second-line therapy.

How Subcutaneous vs IV May Affect Treatment Adherence in Cancer Care

January 27th 2025, 2:00pm

By Ryan Scott

Article

Dr. Eric K. Singhi shares his insights into the advantages of the subcutaneous formulation of Opdivo versus the IV version for patients with solid tumors.

Study Shows Poor Outcomes in BRAF V600E-Mutant Metastatic CRC

January 26th 2025, 7:00pm

By Russ Conroy

Article

Synchronous metastases did not affect survival in resected BRAF V600E-mutated metastatic colorectal cancer.

The BREAKWATER Trial Explores Braftovi, Erbitux and Chemo in BRAF V600E+ mCRC

January 26th 2025, 3:00pm

By Ryan Scott

Video

Dr. Scott Kopetz discusses the BREAKWATER trial investigating Braftovi and Erbitux plus chemo in those with BRAF V600E+ metastatic colorectal cancer.

Neoadjuvant Keytruda Shows Significant Benefit in dMMR Colon Cancer

January 25th 2025, 8:30pm

By Ariana Pelosci

Article

Neoadjuvant Keytruda for patients with deficient DNA mismatch repair colon cancer resulted in a pathological complete response rate of 44%.

ctDNA Status May Predict Disease-Free Survival With Celebrex in Colon Cancer

January 25th 2025, 7:58pm

By Ashling Wahner

Article

Although ctDNA positivity generally meant worse disease-free survival in stage 3 resected colon cancer, patients with ctDNA who received Celebrex had significantly better rates versus placebo.

Afinitor Plus Somatuline May Improve Survival in Aggressive GEP-NETs

January 25th 2025, 7:36pm

By Darlene Dobkowski, MA

Video

Dr. Susumu Hijioka spoke about the benefit of this combination therapy in patients with unresectable or recurrent GEP-NETs, particularly those with high Ki-67 scores.

CRT and Chemo May Not Improve Survival in Resected Gallbladder Cancer

January 25th 2025, 5:43pm

By Ariana Pelosci

Article

Among patients with resected gallbladder cancer, the addition of chemoradiation to chemotherapy treatment did not improve relapse-free survival.